Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Indiana: - Parkview Regional Medical Center — Fort Wayne, Indiana
- Goshen Center for Cancer Care — Goshen, Indiana
- Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
- Richard L. Roudebush Veterans Affairs Medical Center — Indianapolis, Indiana
- Franciscan Health Indianapolis — Indianapolis, Indiana
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04402788
Sites in Indiana: - Northwest Cancer Center - Main Campus — Crown Point, Indiana
- Northwest Oncology LLC — Dyer, Indiana
- Northwest Cancer Center - Hobart — Hobart, Indiana
- Saint Mary Medical Center — Hobart, Indiana
- The Community Hospital — Munster, Indiana
Phase 3 Recruiting Academic/Other
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632327
Sites in Indiana: - Goshen Center for Cancer Care — Goshen, Indiana
- Reid Health — Richmond, Indiana
Phase 3 Recruiting NIH
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in Indiana: - IU Health West Hospital — Avon, Indiana
- IU Health North Hospital — Carmel, Indiana
- Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
Phase 3 Recruiting Network
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…
Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in Indiana: - Riley Hospital for Children — Indianapolis, Indiana
Phase 3 Recruiting Industry
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in Indiana: - Clinical Study Site — Indianapolis, Indiana
Phase 3 Recruiting Industry
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…
Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in Indiana: - Parkview Research Center at Parkview Regional Medical Center — Fort Wayne, Indiana
- Franciscan Health — Indianapolis, Indiana
Phase 3 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…
Sponsor: AbbVie
NCT ID: NCT04928846
Sites in Indiana: - Goshen Center for Cancer Care /ID# 257734 — Goshen, Indiana
- Investigative Clinical Research of Indiana - Indianapolis /ID# 260468 — Indianapolis, Indiana
Phase 3 Recruiting Industry
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tir…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312137
Sites in Indiana: - Parkview Research Center at Parkview Regional Medical Center ( Site 0089) — Fort Wayne, Indiana
- Indiana University Health Arnett Cancer Center ( Site 0076) — Lafayette, Indiana
Phase 3 Recruiting Industry
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in Indiana: - Local Institution - 0454 — Dyer, Indiana
- Local Institution - 0684 — Fort Wayne, Indiana
- Local Institution - 0423 — Munster, Indiana
Phase 3 Recruiting Industry
The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
Sponsor: Amgen
NCT ID: NCT07005128
Sites in Indiana: - Indiana University Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
Phase 3 Recruiting Industry
The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced o…
Sponsor: AstraZeneca
NCT ID: NCT06350097
Sites in Indiana: - Research Site — Fort Wayne, Indiana
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Indiana: - Indiana University — Goshen, Indiana
Phase 3 Recruiting Industry
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (E…
Sponsor: Gilead Sciences
NCT ID: NCT06801834
Sites in Indiana: - Parkview Research Center — Fort Wayne, Indiana
- IU Health Ball Memorial Hospital and Physicians - Cancer Center - Muncie — Muncie, Indiana
Phase 2 Recruiting Network
This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Indiana: - Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
Phase 2 Recruiting NIH
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03191149
Sites in Indiana: - Reid Health — Richmond, Indiana
Phase 2 Recruiting Network
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the M…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06116682
Sites in Indiana: - Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
Phase 2 Recruiting Industry
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-smal…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06667076
Sites in Indiana: - Fort Wayne Medical Oncology and Hematology — Fort Wayne, Indiana
- Investigative Clinical Research of Indiana, LLC — Noblesville, Indiana
Phase 2 Recruiting Industry
This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this stud…
Sponsor: Boehringer Ingelheim
NCT ID: NCT05882058
Sites in Indiana: - Indiana University — Indianapolis, Indiana
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Sponsor: GV20 Therapeutics
NCT ID: NCT05669430
Sites in Indiana: - Community Health Network, Inc. — Indianapolis, Indiana
Phase 1, Phase 2 Recruiting Industry
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06922591
Sites in Indiana: - University of Indiana — Indianapolis, Indiana
Phase 1, Phase 2 Recruiting Federal
Randomized phase 2, multicenter, biomarker directed clinical trial with a safety lead-in to assess the efficacy of Stenoparib plus Temozolomide (TMZ) in relapsed Small Cell Lung Cancer patients. Participants will receive either a combinati…
Sponsor: VA Office of Research and Development
NCT ID: NCT06681220
Sites in Indiana: - Richard L. Roudebush VA Medical Center, Indianapolis, IN — Indianapolis, Indiana
Phase 2 Recruiting Industry
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is …
Sponsor: AbbVie
NCT ID: NCT07155174
Sites in Indiana: - Fort Wayne Medical Oncology And Hematology /ID# 277336 — Fort Wayne, Indiana
Phase 2 Recruiting Federal
This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.
Sponsor: VA Office of Research and Development
NCT ID: NCT06275360
Sites in Indiana: - Richard L. Roudebush VA Medical Center, Indianapolis, IN — Indianapolis, Indiana
Phase 2 Recruiting Academic/Other
This phase II trial studies the effects of temozolomide and atezolizumab as second or third line treatment for patients with small cell lung cancer that has spread to other places in the body (metastatic) or has come back (recurrent). Chem…
Sponsor: Dwight Owen
NCT ID: NCT04919382
Sites in Indiana: - Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana